Translations:Management of obesity/25/en: Difference between revisions

From Azupedia
Jump to navigation Jump to search
VisualWikitext
FuzzyBot (talk | contribs)
15,166 edits
Importing a new version from external source
 
(No difference)

Latest revision as of 15:44, 4 March 2024

Information about message (contribute)
This message has no documentation. If you know where or how this message is used, you can help other translators by adding documentation to this message.
Message definition (Management of obesity)
=== Anti-obesity medications currently approved by the FDA for weight loss ===
Several anti-obesity medications are currently approved by the FDA for long term use.
* Semaglutide (Wegovy) is currently approved by the FDA for long-term use, being associated with a 6-12% loss in body weight compared to placebo.
* The [[combination drug]] [[phentermine/topiramate]] (Qsymia) is approved by the FDA as an addition to a reduced-calorie diet and exercise for chronic [[weight management]].
* Orlistat reduces intestinal fat absorption by inhibiting pancreatic [[lipase]]. Over the longer term, average weight loss on orlistat is 2.9kg. It leads to a reduced incidence of diabetes, and has some effect on [[cholesterol]]. However, there is little information on how it affects the longer-term complications or outcomes of obesity.
* [[Racemic amphetamine]], [[phendimetrazine]], [[diethylpropion]], and [[phentermine]] are approved by the FDA for short term use.

Anti-obesity medications currently approved by the FDA for weight loss

Several anti-obesity medications are currently approved by the FDA for long term use.

  • Semaglutide (Wegovy) is currently approved by the FDA for long-term use, being associated with a 6-12% loss in body weight compared to placebo.
  • The combination drug phentermine/topiramate (Qsymia) is approved by the FDA as an addition to a reduced-calorie diet and exercise for chronic weight management.
  • Orlistat reduces intestinal fat absorption by inhibiting pancreatic lipase. Over the longer term, average weight loss on orlistat is 2.9kg. It leads to a reduced incidence of diabetes, and has some effect on cholesterol. However, there is little information on how it affects the longer-term complications or outcomes of obesity.
  • Racemic amphetamine, phendimetrazine, diethylpropion, and phentermine are approved by the FDA for short term use.
Retrieved from "https://wiki.tiffa.net/w/index.php?title=Translations:Management_of_obesity/25/en&oldid=124306"